European Gas Prices Rise on Middle-East Supply Risks
0754 GMT – European natural-gas prices rise in early trade as escalating tensions between Israel and Iran threaten energy flows in the region. The benchmark Dutch TTF contract is up 1.7% to 38.53 euros a megawatt hour. 'Iran doesn't export any meaningful supplies of natural gas, as its gas operations meet its domestic requirements,' ANZ Research analysts say. 'However, the Strait of Hormuz is an important waterway for LNG. It handles about a fifth of the world's LNG supply, mostly from Qatar.' Meanwhile, Israel shut down production at its biggest natural-gas field, the Leviathan, a key source of LNG supplies for Egypt. Analysts warn this could prompt Egypt to increase purchases on the spot market in order to meet its domestic demand, tightening global supplies. (giulia.petroni@wsj.com)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Stock market today: Dow, S&P 500, Nasdaq rise, oil slips as Israel-Iran conflict enters 4th day
US stocks climbed on Monday, eyeing a rebound as jitters over a widening in the Israel-Iran conflict started to recede despite exchanges of missile strikes throughout the weekend. The Dow Jones Industrial Average (^DJI) rose 0.6%, while the S&P 500 (^GSPC) also moved up 0.6%. The Nasdaq Composite (^IXIC) gained 0.8%. The cautious optimism follows a bruising Friday session that saw the Dow plunge more than 700 points in a broad risk-off move. Meanwhile, oil (CL=F) prices edged lower after jumping in the wake of the latest attacks, having surged last week to their highest levels since January. The geopolitical flare-up comes at a delicate moment for markets already buffeted by tariff insecurity. Friday's selloff dragged the major US indexes into negative territory for the week. Read more: The latest on Trump's tariffs Now investors are regaining some appetite for risk amid rising optimism that the conflict won't spill over into a broader regional crisis. President Trump said on Sunday there's a "good chance" of an Israel-Iran peace deal, but the hostilities may need to play out first. 'Sometimes they have to fight it out, but we're going to see what happens,' he told reporters. A measure of calm is also returning to the oil market, rattled by fears of disruption to the global energy supply. After spiking initially, prices pushed down nearly 2% to pull Brent crude (BZ=F) to just under $73 a barrel and WTI crude to below $72 a barrel. Gold (GC=F) prices also pulled back, having rallied alongside oil as it drew safe-haven flows amid rising volatility. The precious metal traded lower at around $3,443 an ounce. On the trade front, the EU is reportedly ready to accept US tariffs of 10% across all its exports — the baseline for Trump's "reciprocal" hikes — as the president puts pressure on trading partners to reach a deal. The offer is a bid to avert higher rates on cars, drugs, and electronics, Handelsblatt reported. Looking ahead, markets overwhelmingly expect the Fed to hold rates steady on Wednesday. While President Trump has maintained pressure on Chair Jerome Powell to cut rates, current market dynamics may leave little room to budge. The major averages opened higher on Monday, while oil pulled back as the Israel-Iran conflict entered its fourth day. The Dow Jones Industrial Average (^DJI) gained about 0.5%, while the S&P 500 (^GSPC) moved up 0.6%. The tech-heavy Nasdaq Composite (^IXIC) rose 0.7%. Oil (CL=F), which rose sharply on Friday, pulled back as traders assessed the scope of the ongoing conflict between Israel and Iran. Investors are focusing this week on the Federal Reserve meeting and policy decision. Market participants overwhelmingly expect policymakers to hold interest rates steady on Wednesday. Strategy (MSTR), the largest corporate holder of bitcoin, reported in a filing to the Securities and Exchange Commission that it purchased $1.05 billion worth of bitcoin between June 9 and June 15. Strategy, which is chaired by crypto tycoon Michael Saylor, has spent $41.8 billion to purchase 592,000 bitcoins since 2020, holding the cryptocurrency as its primary treasury reserve asset. Shares of MSTR rose 1.4% in premarket trading. The stock is up roughly 3,000% since the software firm first bought bitcoin on Aug. 10, 2020. Northrop Grumman (NOC), RTX (RTX), and Lockheed Martin (LMT) traded roughly flat in premarket Monday after rallying in the prior trading session. The defense stocks had climbed Friday after Israel launched a series of airstrikes on Iran, raising tensions in the Middle East and heightening fears of a broader regional conflict. Northrop Grumman stock gained nearly 4%, while Lockheed Martin and RTX shares rose over 3%. The three companies supply weapons to Israel through contracts with the US government. Palantir (PLTR) rose a more modest 1.6% Friday but was up 2.2% before the market open Monday. Shares of Sarepta (SRPT) plunged 40% in premarket trading on Monday after the company said a second patient died of liver failure while taking its experimental gene therapy, Elevidys. Sarepta paused its clinical trial and halted shipments of the treatment to patients who are unable to walk. News of the death comes after another patient died of acute liver failure in March, which raised concerns over the drug's safety. The therapy is used to treat Duchenne muscular dystrophy, a rare muscle disorder. The focus at this week's Federal Reserve meeting is on whether policymakers are still committed to two interest-rate cuts this year, Yahoo Finance's Jennifer Schonberger reports: Read more here. Here are some of the biggest stories you may have missed over the weekend and early this morning: Economic data: Empire manufacturing activity (June) Earnings: No notable earnings. How many Fed cuts ahead? We (and Trump) are about to find out. EU set to accept flat 10% US tariff — with conditions Mideast tensions, Fed's 'dot plot': What to know this week Oil erases gain as Iran-Israel attacks spare critical flows Why Wall Street doesn't see Fed rate cuts coming anytime soon Investors shun long-term US bonds as rate-cut hopes fade Israel-Iran attacks enter 4th day with no deal in sight Here are some top stocks trending on Yahoo Finance in premarket trading: United States Steel Corporation (X) stock was up 5% before the bell on Monday after President Trump approved of Japan's Nippon Steel's take over of the company. Trump the gave the green light to the $14.9B bid for US Steel on Friday, removing a key hurdle in Nippon's 18-month pursuit of the business. Kering's ( Paris-listed shares rose 9% in premarket trading on Monday, after reports emerged that Renault's chief executive, Luca de Meo would become head of the French luxury goods group Gucci. Tesla (TSLA) stock was up 1% on Monday before the bell, rebounding from losses earlier in the Month due to CEO Elon Musk and President Trump's feud. Renault's ( stock dropped over 6% on news that its CEO Luca de Meo has decided to leave. The Italian who turned around the French automaker has been recruited by Kering (PPXB.F, PPRUF) to perform a similar feat at the luxury goods maker, according to Bloomberg. Shares of Kering rose almost 10% in Paris as investors welcomed the report that de Meo will be appointed as the Gucci owner's CEO in coming days. Bloomberg reports: Read more here. Greetings from Cannes Lions, where I am stationed for the week talking with top advertising execs, sports stars and CEOs. Tough assignment! I have found this event to be very useful each year in helping to understand the economy into year end. You would be surprised how forward-looking market spend trends are at the world's biggest companies. To that end, I just got off set with Disney's (DIS) president of global advertising Rita Ferro — one of the top names in the marketing industry. I asked her if a slowing US economy and general macro volatility were beginning to chip away at ad budgets. She wasn't super bullish about ad spending — more cautiously optimistic. Businesses are buying ads once they see they need them, rather than making large commitments on ad spend early, she suggested. "I think people are being very intentional where they spend money," Ferro tells me. "I would say they're [the data points she watches] not recessionary. We see much closer in buying." Gold prices rose as the conflict erupting between Israel and Iran pushed investors toward safe-haven assets in a broader risk-off move. Bloomberg reports: Read more here. Oil continues to gain as Israel and Iran enter the fourth consecutive day of missile strikes between the warring nations. Iran is the third largest oil producer in OPEC+ and controls the Strait of Hormuz, an essential supply route for oil worldwide. Bloomberg reports: Read more here. The major averages opened higher on Monday, while oil pulled back as the Israel-Iran conflict entered its fourth day. The Dow Jones Industrial Average (^DJI) gained about 0.5%, while the S&P 500 (^GSPC) moved up 0.6%. The tech-heavy Nasdaq Composite (^IXIC) rose 0.7%. Oil (CL=F), which rose sharply on Friday, pulled back as traders assessed the scope of the ongoing conflict between Israel and Iran. Investors are focusing this week on the Federal Reserve meeting and policy decision. Market participants overwhelmingly expect policymakers to hold interest rates steady on Wednesday. Strategy (MSTR), the largest corporate holder of bitcoin, reported in a filing to the Securities and Exchange Commission that it purchased $1.05 billion worth of bitcoin between June 9 and June 15. Strategy, which is chaired by crypto tycoon Michael Saylor, has spent $41.8 billion to purchase 592,000 bitcoins since 2020, holding the cryptocurrency as its primary treasury reserve asset. Shares of MSTR rose 1.4% in premarket trading. The stock is up roughly 3,000% since the software firm first bought bitcoin on Aug. 10, 2020. Northrop Grumman (NOC), RTX (RTX), and Lockheed Martin (LMT) traded roughly flat in premarket Monday after rallying in the prior trading session. The defense stocks had climbed Friday after Israel launched a series of airstrikes on Iran, raising tensions in the Middle East and heightening fears of a broader regional conflict. Northrop Grumman stock gained nearly 4%, while Lockheed Martin and RTX shares rose over 3%. The three companies supply weapons to Israel through contracts with the US government. Palantir (PLTR) rose a more modest 1.6% Friday but was up 2.2% before the market open Monday. Shares of Sarepta (SRPT) plunged 40% in premarket trading on Monday after the company said a second patient died of liver failure while taking its experimental gene therapy, Elevidys. Sarepta paused its clinical trial and halted shipments of the treatment to patients who are unable to walk. News of the death comes after another patient died of acute liver failure in March, which raised concerns over the drug's safety. The therapy is used to treat Duchenne muscular dystrophy, a rare muscle disorder. The focus at this week's Federal Reserve meeting is on whether policymakers are still committed to two interest-rate cuts this year, Yahoo Finance's Jennifer Schonberger reports: Read more here. Here are some of the biggest stories you may have missed over the weekend and early this morning: Economic data: Empire manufacturing activity (June) Earnings: No notable earnings. How many Fed cuts ahead? We (and Trump) are about to find out. EU set to accept flat 10% US tariff — with conditions Mideast tensions, Fed's 'dot plot': What to know this week Oil erases gain as Iran-Israel attacks spare critical flows Why Wall Street doesn't see Fed rate cuts coming anytime soon Investors shun long-term US bonds as rate-cut hopes fade Israel-Iran attacks enter 4th day with no deal in sight Here are some top stocks trending on Yahoo Finance in premarket trading: United States Steel Corporation (X) stock was up 5% before the bell on Monday after President Trump approved of Japan's Nippon Steel's take over of the company. Trump the gave the green light to the $14.9B bid for US Steel on Friday, removing a key hurdle in Nippon's 18-month pursuit of the business. Kering's ( Paris-listed shares rose 9% in premarket trading on Monday, after reports emerged that Renault's chief executive, Luca de Meo would become head of the French luxury goods group Gucci. Tesla (TSLA) stock was up 1% on Monday before the bell, rebounding from losses earlier in the Month due to CEO Elon Musk and President Trump's feud. Renault's ( stock dropped over 6% on news that its CEO Luca de Meo has decided to leave. The Italian who turned around the French automaker has been recruited by Kering (PPXB.F, PPRUF) to perform a similar feat at the luxury goods maker, according to Bloomberg. Shares of Kering rose almost 10% in Paris as investors welcomed the report that de Meo will be appointed as the Gucci owner's CEO in coming days. Bloomberg reports: Read more here. Greetings from Cannes Lions, where I am stationed for the week talking with top advertising execs, sports stars and CEOs. Tough assignment! I have found this event to be very useful each year in helping to understand the economy into year end. You would be surprised how forward-looking market spend trends are at the world's biggest companies. To that end, I just got off set with Disney's (DIS) president of global advertising Rita Ferro — one of the top names in the marketing industry. I asked her if a slowing US economy and general macro volatility were beginning to chip away at ad budgets. She wasn't super bullish about ad spending — more cautiously optimistic. Businesses are buying ads once they see they need them, rather than making large commitments on ad spend early, she suggested. "I think people are being very intentional where they spend money," Ferro tells me. "I would say they're [the data points she watches] not recessionary. We see much closer in buying." Gold prices rose as the conflict erupting between Israel and Iran pushed investors toward safe-haven assets in a broader risk-off move. Bloomberg reports: Read more here. Oil continues to gain as Israel and Iran enter the fourth consecutive day of missile strikes between the warring nations. Iran is the third largest oil producer in OPEC+ and controls the Strait of Hormuz, an essential supply route for oil worldwide. Bloomberg reports: Read more here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Why this week's Fed meeting likely won't help stocks break out to new highs
Investors are heading into the coming week's two-day Federal Reserve meeting facing a wide band of uncertainty around the path ahead for the U.S. economy, inflation, and interest rates — which has the potential to keep stocks rangebound, make them more volatile, or both through the end of the year. An anticipated spike in inflation from trade wars has yet to materialize, as demonstrated by mild data on consumer- and producer prices for May. Tensions in the Middle East sparked by Israel's attack on Iran's nuclear program early Friday caused oil futures to soar as much as 14% overnight in the U.S. before paring back the same day, and raised concerns in the bond market about the potential impact on overall prices. Israel-Iran clash delivers a fresh shock to investors. History suggests this is the move to make. I'm in my 80s and have 2 kids. How do I choose between them to be my executor? My husband is in hospice care. Friends say his children are lining up for his money. What can I do? 'He failed in his fiduciary duty': My brother liquidated our mother's 401(k) for her nursing home. He claimed the rest. Israel's attack on Iran shattered stocks' early-summer calm. Here's what investors should watch out for next. The question now is whether an inflation spike is still on the way, how Fed officials might react to this, and whether they'll need to keep rates at current levels for longer or cut borrowing costs as soon as September to prevent the current economic slowdown from turning into a recession. Read: How Iran's response to Israel's strike could shake up global markets — in 5 scenarios 'Uncertainty is still the name of the game,' said Jim Baird, chief investment officer with Plante Moran Financial Advisors in Michigan. 'Policy uncertainty — predominantly trade policy, which has a direct impact on what the Fed will do — has been the primary driver around the near-term outlook for the economy and the market.' A spike in oil due to the escalating Mideast conflict adds another layer of uncertainty and, if sustained, could weigh on household spending, he added. 'The economy is not out of the woods and we cannot say definitively that inflation will not be an issue in the coming months, particularly if oil prices move — and stay — higher,' Baird said via phone. For most investors, this 'speaks to the need to be broadly diversified and have a plan focused on a time horizon that may span decades rather than just a few months. Trying to time the market is a fool's errand. Make sure to have adequate cash reserves and don't give in to the temptation to take significant action driven by fear in the face of uncertainty.'After a steep runup in U.S. stocks since April fueled by investors' short-term optimism over trade policies, bulls have been looking for a new catalyst to fuel a final push back into record territory for the S&P 500 SPX. But there are reasons why Federal Reserve Chairman Jerome Powell won't likely be able to provide one on Wednesday, which could leave market participants vulnerable to Fed officials are expected to update their economic and interest-rate projections, Powell is not likely to say much of anything that's new about the U.S. outlook. Strategists at TD Securities said they expect him to be 'noncommittal' and to repeat his view that the Fed remains well-positioned to wait for greater clarity before adjusting rates. The team at TD also sees a risk that policymakers will pencil in just one interest-rate cut for 2025, down from the two reductions which officials anticipated in March. Given continued trade uncertainty, some observers such as Mark Hackett, chief market strategist at Ohio-based financial-services company Nationwide, said that a breakthrough to record highs in the S&P 500 will likely require a new catalyst, like a rebound in earnings trends. As of Friday, the index was up almost 20% since its year-to-date closing low of 4,982.77 reached on April 8. With the exception of Friday's performance, it's mostly traded above 6,000 since June 6, but hasn't been able to surpass its record closing high of 6,144.15 from Feb. 19. Read: The S&P 500 is nearly back to record highs, but investors shouldn't get too comfortable . Meanwhile, the Economic Policy Uncertainty Index, a preferred measure of uncertainty for investment giants like Vanguard, is at its highest level on record in the U.S. as of June, based on monthly readings. When policy uncertainty runs this high, it tends to mean that consumers will pull back on spending, businesses will cut or defer investments, and there will be less demand for labor, according to one of the co-creators of the index, Steven Davis at Stanford University's Hoover Institution. Any of these factors which tip the economy closer to a recession has the potential to justify the two 2025 quarter-point rate cuts currently projected by the Fed and fed-funds futures traders. But tariffs and trade-policy uncertainty are a dual-edged sword: They could either exacerbate the current economic slowdown, or lead to a longer period of above-2% inflation that leaves the central bank sitting on its hands and doing nothing through December. Higher oil prices can have a similar dual-edged Adams, chief economist for Comerica Bank in Dallas, is among those who expect the Fed to leave the fed-funds rate target unchanged at between 4.25% and 4.5% through year-end. By contrast, senior economist Lauren Henderson of Stifel, Nicolaus & Co. in Chicago said her firm expects two rate cuts this year, but the 'window of opportunity' for the Fed to deliver them is starting to close given the upside risks to inflation in the second half of this year. At CIBC Private Wealth, Gary Pzegeo, a Boston-based co-chief investment officer, said a wide band of uncertainty around trade policies, the economy and interest rates makes it a good idea for investors 'to do some hedging or diversification around those outcomes. 'The simplest way to do that is to spread your bets. So if you overweight U.S. equities, try to incorporate some non-dollar related positions. It could also be just increasing cash,' said Pzegeo, whose firm had $102.1 billion in assets under management and administration as of April. 'By definition, if there is a wider range of outcomes expected, then there should be a wider range of equity market returns. Certainly, the two go together,' he said, citing the S&P 500's almost 19% drop between February and April, which was followed by an almost 20% rise through June. 'We've just gone through a very volatile period and perhaps investors will be a little more prepared in terms of surprises to trade policies.' In other words, they may not see a single headline as a tradable event and 'don't react as much as the first time around.'All three major U.S. stock indexes finished sharply lower on Friday after Iran responded to Israel's attack with missiles over Tel Aviv. The Dow Jones Industrial Average DJIA, S&P 500 and Nasdaq Composite COMP each closed with their biggest one-day declines since May 21, and largest weekly drops since the period that ended on May 23. Wednesday's Fed policy statement, updated forecasts, and press conference by Powell are the biggest events of the coming week. Monday brings the release of the Empire State manufacturing survey for June. The following day, May data is released on U.S. retail sales, industrial production, capacity utilization and import prices, along with June's home builder confidence Wednesday, data arrives on housing starts and building permits for May, as well as weekly jobless claims. Financial markets are closed on Thursday for the Juneteenth holiday. Friday brings the Philadelphia Fed manufacturing survey for June. These defense stocks offer the best growth prospects, as the Israel-Iran conflict fuels new interest in the sector Israel-Iran conflict poses three challenges for stocks that could slam market by up to 20%, warns RBC My mother-in-law, 95, has $400K in stocks. Would it be smarter taxwise to gift it to her kids — or leave it to them in her will? There-is-no-alternative gets a revival as U.S. households snap up stocks 'I'm 68 and my 401(k) has dwindled to $82,000': My husband committed financial infidelity and has $50,000 in credit-card debt. What now? Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
Ramat Gan, Israel, June 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that Dr. Sari Fishman, Vice President of Business Development, will present an update on the Company's ongoing Phase IIa study in pancreatic cancer during partnering meetings at the 2025 BIO International Convention, taking place June 16–19 in Boston, MA (link). The Phase IIa clinical trial is open-label study evaluating Namodenoson in patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one prior line of therapy. The study is assessing the safety, clinical activity, and pharmacokinetics (PK) of Namodenoson, administered orally at a dose of 25 mg twice daily in continuous 28-day cycles. Approximately 20 evaluable patients are expected to be enrolled. The trial is led by Prof. Salomon Stemmer, a prominent Oncologist and Key Opinion Leader at the Davidoff Center, Rabin Medical Center, Israel. Namodenoson has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. 'We are pleased to report that 50% of the planned patient cohort has already been enrolled and that Namodenoson has demonstrated a favourable safety profile,' stated Prof. Salomon Stemmer. 'There is a critical unmet need for safe and effective treatment options for patients with advanced pancreatic cancer who have exhausted standard therapies. This study gives us the opportunity to advance a novel therapeutic approach for this challenging disease, stated Dr. Sari Fishman, VP of Business Development at Can-Fite.' Can-Fite looks forward to engaging with potential partners and collaborators at BIO 2025 as it continues to progress its clinical pipeline. About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: Forward-Looking Statements This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are 'forward looking statements'. Forward-looking statements can be identified by the use of forward-looking words such as 'believe,' 'expect,' 'intend,' 'plan,' 'may,' 'should' or 'anticipate' or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offerings, the satisfaction of customary closing conditions related to the offerings and the intended use of proceeds therefrom. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the 'Risk Factors' section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contact Can-Fite BioPharma Motti Farbstein info@ +972-3-9241114Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
